![]()
|
|
||||||||
J. Biol. Chem., Vol. 277, Issue 51, 49332-49340, December 20, 2002
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
§,
¶,
,
§,
,
,
,
¶¶
From the
Laboratório de Espectrometria de
Massa, Empresa Brasileira de Pesquisa Agropecuária
(EMBRAPA) - Recursos Genéticos e Biotecnologia,
Estação Parque Biológico, Final W5, Asa Norte,
Brasília, DF, 70770-900 Brasil, ¶ Departamento de Biologia
Celular, Instituto de Biologia, Universidade de Brasília,
70910-900 Brasil,
Departamento de Genética e Morfologia,
Universidade de Brasília, Brasil, Instituto de Biologia,
Universidade de Brasília, 70910-900 Brasil,
** Departamento de Ciências Farmacêuticas,
Faculdade de Ciências Farmacêuticas de Ribeirão
Preto, Universidade de São Paulo, 05508-900 Brasil,

Departamento de Bioquímica e
Imunologia da Escola de Medicina de Ribeirão Preto, Universidade
de São Paulo, Brasil, §§ Laboratorio SABIN
de Análises Clínicas, Brasília, Brasil, and
§ Instituto de Biologia, Universidade de Brasília,
70910-900 Brasil
Received for publication, September 11, 2002, and in revised form, October 9, 2002
| |
ABSTRACT |
|---|
|
|
|---|
Amphibian skin secretions are known as a rich
source of biologically active molecules, most of which are alkaloids,
biogenic amines, and peptides. Dermaseptins are a class of
antimicrobial peptides present in tree frogs of the
Phyllomedusa genus. They are cationic molecules of
28-34 residues that permeabilize the membrane of Gram-positive and
Gram-negative bacteria, yeasts, and filamentous fungi, showing little
or no hemolytic activity. This work reports the isolation, molecular
mass analysis, primary structure determination, biological activities,
and potential therapeutic applications of an antimicrobial peptide
found in the skin secretion of Phyllomedusa oreades, which
is a newly described amphibian species endemic of the Brazilian
savanna. DS 01 is a 29-residue-long peptide with a molecular mass of
2793.39 Da showing antibacterial properties against Gram-positive and
Gram-negative bacteria in the range of 3-25 µM.
Anti-protozoan activity was investigated using T. cruzi in
its trypomatigote and epimastigote forms cultivated in both cell
culture and blood media. Within 2 h after incubation with DS 01 at
a final concentration of ~6 µM, no protozoan cells were
detected. Two synthetic dermaseptins, described previously by our group
and named dermadistinctins K and L (DD K and DD L), also had their
anti-Trypanosoma cruzi activity investigated and
demonstrated similar properties. Toxicity of DS 01 to mouse
erythrocytes and white blood cells was evaluated by means of atomic
force microscopy and flow cytometry. No morphological alterations were
observed at a lytic concentration of DS 01, suggesting its therapeutic
value especially as an anti-T. cruzi agent to prevent
infections during blood transfusion.
The synthesis of gene-encoded antimicrobial peptides as an immune
strategy is widely used in nature and has been conserved during
evolution. Antimicrobial peptides have been produced by a number of
Gram-positive and Gram-negative bacteria for billions of years to
hinder the proliferation of other microorganisms that are closely
related or confined within the same ecological niche (1-6). In
vertebrates, these peptides are synthesized by lymphoid cells, granular
epithelial cells of the skin, respiratory and urogenital tracts, and
also by the gastrointestinal system (7-10). A defense strategy against
invading microorganisms is well documented in amphibians and consists
of the biosynthesis of a large number of small polycationic peptides
integrated with the cell-mediated immune system.
Several antimicrobial peptides have been isolated from anuran species,
and among the most studied are the ones from the dermaseptin family.
Dermaseptins are molecules found in the skin secretion of tree frogs
from the Phyllomedusinae subfamily. They consist of a
characteristic polypeptide chain of 28-34 amino acids with 3-6 lysine
residues and a very conserved tryptophan residue in the third position
from the N terminus (10, 11). These peptides exert a lytic action on
bacteria, protozoa, yeast, and filamentous fungi at micromolar
concentrations. Unlike polylysines, the dermaseptins show little or no
detectable hemolytic activity (11, 12).
The capacity of the dermaseptins to discriminate between mammalian and
microbial cells has been known for more than a decade (13, 14), and it
is mainly due to the amino acid composition of the peptides and to the
differences encountered in the physical-chemical properties of
membranes (13-20). Besides the phospholipid content, the cell lysis
mediated by amphiphilic antimicrobial peptides such as the dermaseptins
is attenuated by increasing amounts of membrane cholesterol (21, 22).
The membrane of the Trypanosoma cruzi trypomastigote forms
was demonstrated to be composed mostly of phosphatidylcholine and to a
lesser extent phosphatidylethanolamine (23). There are no published
data regarding the presence of cholesterol in T. cruzi
bloodstream forms, although it has been shown to exist in high molar
ratios in Trypanosoma brucei (24). Since T. cruzi
cannot synthesize cholesterol, its source is restricted to the growth
medium extraction (25), whereas in T. brucei, it is derived from host low density
lipoprotein particles (26). The potential susceptibility of
Trypanosomatidae to cationic amphiphilic peptides was stated
by the discovery that apolipoprotein-A, which shares many features with
antimicrobial peptides, has a trypanocidal effect on T. brucei (27).
Ultimately, there has been a growing interest in using dermaseptins as
therapeutical agents in diseases caused by protozoa (28-30). Indeed,
chemically modified dermaseptins have already been shown to effectively
lyse the intra-erythrocytic form of Plasmodium falciparum,
leaving the host cell unharmed (30). However, there is still a long way
before dermaseptins can be considered as an actual and efficient
therapy against protozoa infections since their interactions with
mammalian blood cells are still poorly investigated.
The present work describes the isolation, molecular mass determination,
and complete amino acid sequencing of a new dermaseptin, named DS
01,1 isolated from the skin
secretion of the recently identified species Phyllomedusa
oreades (31). Due to the observed lytic action against a wide
range of microorganisms, we also investigated the activity of DS 01 against T. cruzi. This protozoan pathogen is the causative
agent of Chagas' disease, which affects 16-18 million people in
Central and South America (32). About 20,000 new cases are reported
each year, all due to contaminated blood transfusions (33), thus
creating a strong demand for effective trypanocidal agents that are
non-toxic for blood cells and have little or no side effects.
The interaction of DS 01 with blood cells is investigated in a more
comprehensive way than the conventional hemolysis assay. Possible
cytotoxic effects on white blood cells and platelets were investigated
by the use of flow cytometry, complemented by morphological
observations under light microscope. Atomic force microscopy was also
used to investigate any detectable morphological alterations of mice
erythrocytes exposed to dermaseptins at high concentrations.
Amphibians--
Frog skin secretion (crude extract) was obtained
from adult specimens of P. oreades, a new specimen of the
Phyllomedusinae subfamily captured in Serra da Mesa
(Goiás), Central Brazil and described by Brandão (31). The
Instituto Brasileiro do Meio Ambiente e dos Recursos Renováveis
(IBAMA) license number was 097/96-DIFAS, and the process number was
0637/91A.C.
Peptide Purification--
Frog secretion was obtained by mild
electric stimulation of the granular skin glands of P. oreades and freshly collected in distilled water as a soluble
extract. The extract was filtered by gravity through filter paper,
frozen, and lyophilized (Centrivap Concentrador, Labconco, Kansas City,
MO). Peptide separation was performed by injecting 250 µl of the
crude extract to a semipreparative Vydac 218 TP 510 (Hesperia,
CA) reverse-phase chromatographic column, C18, 10 µ (10 × 250 mm) in HPLC1 system (Class LC-10VP from
Shimadzu Corp., Kyoto City, Japan). Peptides were purified by using a
linear gradient from 0 to 70% acetonitrile containing 0.1%
trifluoroacetic acid for 75 min. RP-HPLC experiments were monitored in
two different wavelengths (216 and 280 nm), and fractions were
collected manually and subsequently lyophilized. The isolated fractions
were submitted to a second chromatographic step using a Vydac 218 TP
54, C18, 5 µ (0.46 × 25 cm) column with optimized
gradients of acetonitrile in 0.1% trifluoroacetic acid over 40 min.
Sample purity and mass analyses were made by MALDI-TOF/MS.
Enzymatic Digestion--
The purified peptide was
incubated with 0.5 µg/µl endoproteinase Glu-C (Roche Molecular
Biochemicals) for 18 h at 25 °C. The buffer used was 25 mM ammonium carbonate at pH 7.8 (34, 35).
Molecular Mass Determination, N-terminal, and C-terminal Amino
Acid Sequencing--
The molecular masses of DS 01 and of the two
fragments produced by endoproteinase Glu-C from digestion were
determined by MALDI-TOF/MS (Voyager DE-STR, Applied Biosystems, Foster
City, CA) using close external calibration under reflector mode.
Approximately 20 nmol of lyophilized peptide was dissolved in Milli-Q
water, mixed to a saturated solution of Sequence Comparison--
Dermaseptin DS 01 sequence
alignment and similarity searches were performed using the FASTA 3 program on the Expasy Molecular Server (www.expasy.ch). Secondary
structure prediction was performed using SOPMA, also at Expasy.
DS 01 and Dermadistinctins K (DD K) and L (DD L) Solid-phase
Synthesis--
Amidated DS 01 was synthesized on a Pioneer Synthesis
System from Applied Biosystems. Fmoc amino acids and
Fmoc-PAL-poly(ethyleneglycol)-polystyrene (FmocPAL-PEG-PS) resin were
also purchased from Applied Biosystems. The resin leaves the
amidated C-terminal after peptide extraction. The cleavage and
deprotection procedures, after chemical synthesis, involve the addition
of three scavengers, anisole, ethanedithiol, and thioanisole, in 100%
trifluoroacetic acid (2:3:5:90, v/v). For 0.5 g of resin, 5 ml of
cleavage mixture is needed, and reaction time lasted around 2 h.
The resin was then washed with cold diisopropilic ether, causing
peptide precipitation. 0.1% trifluoroacetic acid and 50% acetonitrile
were then used to recover the crude synthetic peptide. To purify the
peptide, the usage of a preparative C18 column (Vydac 218 TP 1022) on an HPLC system was required. Molecular mass and sample
purity were checked by MALDI/TOF-MS.
DD K and DD L were synthesized using T-Boc amino acids as reported by
Batista et al. (9). Purification of these two synthetic peptides was performed by RP-HPLC in a Vydac 218 TP 54 analytical column, and the purity was checked by MALDI-TOF/MS.
Antimicrobial Activity--
Six bacterial strains were used to
investigate the DS 01 antimicrobial activity. Pseudomonas
aeruginosa ATCC 27853, Staphylococcus aureus ATCC
25923, and Escherichia coli ATCC 25992 were purchased from
American Type Culture Collection. Acetobacter calcoaceticus wild type, E. coli MR, and S. aureus MRSA
(methycilin/oxacylin resistant) were isolated from patients of
the Laboratório SABIN de Análises
Clínicas/Brasília-DF, Brasília, Brazil.
Microorganisms were grown in stationary culture at 37 °C and then
transferred to the Mueller-Hinton liquid medium (National Committee for
Clinical Laboratory Standards (NCCLS)-approved standard M100-S9) in
which the tests were performed (36).
The bacterial liquid growth inhibition assay was performed as described
by Bulet et al. (37). Synthetic DS 01 was dissolved and
diluted 8-fold in Mueller-Hinton broth. The highest peptide concentration used for the assay was 64 µg/ml. The initial inoculum was ~1.8 × 107 colony forming units/ml. The final
volume was 200 µl, 50 µl of the peptide test in broth, 150 µl of
the inoculum in Mueller-Hinton. The experiment was carried on in
stationary culture at 37 °C, and the spectrophotometric readings
were performed 12 h after incubation. The minimal
inhibitory concentration, as introduced by Park et al. (38),
was measured from optical density (A595) and is
the result of three independent measurements.
Conventional antibiotics had their minimum inhibitory concentrations
determined against the six experimental bacterial strains by automated
biochemical analysis (Vitek, bioMériuex Inc.). Initial inoculum
was adjusted to match 0.5 in the McFarland scale. The Mueller-Hinton
broth was the chosen medium.
Trypanocidal Activity--
Bloodstream forms of T. cruzi (Y strain) were harvested from BALB/c mice 7-10 days after
the infection with 105 parasites. The infected blood was
diluted to a final concentration of 5 × 105
parasites/ml with phosphate-buffered saline. The biological tests were
performed as described previously (39). The plates were incubated at
37 °C followed by counting the parasites under a light microscope.
Disappearance or immobility of parasites was judged to indicate drug
action. The experiment was done in triplicate.
Assays for Hemolytic Activity, Erythrocyte, and Leukocyte
Count--
Investigation of the hemolytic activity of synthetic DS 01 was done as reported by Bignami (40). The peptide was diluted serially
and incubated with human red blood cells at 37 °C for 30 min. After
a 900 × g centrifugation for 10 min, the absorbance of
the supernatant phase was measured by spectrophotometry (Microplate Reader 3550, Bio-Rad) at 567 nm. Maximum hemolysis was determined by
adding distilled water to a red blood cell sample.
Leukocyte counts were done as described by Ben-Ezra et al.
(41) and Hove et al. (42). Aliquots of human fresh blood
were collected, preserved in heparin as anticoagulant, and incubated with synthetic DS 01 at 37 °C during 4 h. The final peptide
concentration in solution was 128 µg/ml. Total leukocytes and
platelets counts were done in 200 µl of blood using Cell-Dyn 3500 SC/SL flow cytometry automated hematology analyzer (Abbott
Laboratories, Abbott Park, IL). The data obtained are the result of two
independent measurements. Aliquots of blood subjected to incubation
with synthetic DS 01 were collected and stained by routine Wright's
eosin methylene blue. Morphological monitoring of white blood cells was
done by light microscopy.
Atomic Force Microscopy--
Mouse erythrocytes were freshly
prepared as described by Aboudy et al. (43). Aliquots of 3 ml of freshly prepared erythrocytes were mixed with an anticoagulant
(EDTA) and washed with isotonic phosphate-buffered saline, pH 7.4 (phosphate-buffered saline), until the color of the supernatant turned
clear. The washed erythrocytes were then diluted to a final volume of
20 ml with the same buffer. Peptide samples diluted in
phosphate-buffered saline (12.4 µg/ml) were incubated at 37 °C for
30 min with the cell suspension in a total volume of 190 µl. Another
erythrocyte sample was treated for 5 min with 0.05% Triton X-100 as
positive control to indicate topographic alterations. Control samples
were made in the absence of both peptide and Triton X-100.
An aliquot (4 µl) of each sample was manually spread onto a polished
microscope glass slide to create a blood film, which was rapidly fixed
by air drying. The film was examined under the optical microscope, and
regions with a single layer of red blood cells were marked using a
lens-mounted inking device.
Atomic force microscopy (AFM) was performed in air on the blood film
using a AFM (Explorer model, TopoMetrix, Santa Clara, CA) in contact
mode. The glass slide carrying the blood film was mounted onto
the XY scanner of the AFM, and the integral camera was used to locate
the regions of interest. Contact mode silicon tips with a spring
constant of ~0.3 newtons/m were used. The force applied to the sample
during imaging was typically 15 nanonewtons. Repeated scanning of the
same red blood cells confirmed that no physical damage occurred during
AFM. AFM images were processed and analyzed using the software SPMLab
Version 4.0 (TopoMetrix).
Peptide Purification--
The crude skin secretion fractionation
obtained by RP-HPLC yielded more than 50 fractions (Fig.
1). The DS 01 fraction was submitted to
further purification by using analytical RP-HPLC (Fig.
2A). MALDI-TOF monoisotopic
mass analysis of DS 01 showed an intense ion of [M+H]+ = 2793.39 (Fig. 2B).
Enzymatic digestion of DS 01 using endoproteinase Glu-C resulted
in two fragments called DS 01a and DS 01b (Fig.
3A). Both fragments were
separated by HPLC and showed molecular mass values of
[M+H]+ = 1374.49 and [M+H]+ = 1437.62 Da,
respectively (Fig. 3, B and C).
Primary Structure Determination and Sequence Alignment--
The
primary structure of the intact DS 01 and its enzymatic fragments were
determined by Edman degradation and
carboxypeptidase Y ladder sequencing and are shown in Figs. 4
and 5. The calculated monoisotopic mass of DS 01 and its
fragments (DS 01a and DS 01b) after the
N-terminal sequencing was [M+H]+ = 2794.59 Da. However,
MALDI-TOF/MS data revealed a discrepancy of 1.2 Da for DS01
monoisotopic molecular mass value ([M+H]+ = 2793.39 Da).
A similar difference in mass was also observed when the molecular mass
values for the calculated DS 01b C-terminal fragment
([M+H]+ = 1438.84 Da) were compared with the experimental
result ([M+H]+ = 1437.62 Da) shown in Fig.
3C.
Carboxypeptidase Y ladder sequencing of the intact DS 01 yielded seven
C-terminal residues: (112.16) Ala-Gly-Leu/Ile-Ala-Ala-Lys/Gln (Fig. 5),
suggesting that the C-terminal Leu-29 of DS01 was amidated (Fig.
4). Sequence similarity searches were performed using FASTA 3 program
that runs under the Expasy Molecular Server. This procedure revealed up
to 76% sequence identity with the adenoregulin precursor of
Phyllomedusa bicolor (14) (Table
I).
Secondary Structure Prediction and Helix-Wheel Plot--
The
secondary structure prediction (performed by SOPMA) of the three
peptides investigated in this work (DS 01, DD K, and DD L) indicates a
strong propensity to assume helical conformation. This tendency toward
an Antimicrobial Activity--
Synthetic DS 01 exhibited a broad
spectrum antibacterial activity given that it inhibited the growth of
most of the bacterial strains studied, which included Gram-positive and
Gram-negative strains (Table II).
However, significant differences in the growth inhibition of the
different bacterial strains were observed, in accordance with the
literature published for other dermaseptins (9-12, 45). The DS 01 minimal inhibitory concentration was compared with those obtained by
testing with some conventional antibiotics (gentamicyn, ampicillyn,
imipenem, and ceftazidime), and with minor exceptions, DS 01 was shown
to be far more effective as an antibacterial agent.
Anti-T. cruzi Assay--
Bioassays revealed that DS 01 and the
synthetics DD K and DD L are potent anti-T. cruzi
trypomastigote agents. Fig. 7A
shows that when incubated for 2 h with the protozoan cells in
concentrations up to 4 µg/ml, the peptides are able to lyse most of
the cell population. When the incubation time is increased to 6 h
(Fig. 7B), the same effect is seen with much lower
concentrations (1 µg/ml), regardless of the amino acid composition of
the peptides.
Evaluation of DS 01 Hemolytic Activity and Effect on
Leukocytes--
Investigation of the synthetic DS 01 hemolytic
activity against human red blood cells (Table
III) showed similar lytic levels to other
dermaseptins (9-12). Even in the highest peptide concentration used in
the assay (128 µg/ml), only about 2% of the red blood cells were
lysed. DD K and DD L hemolytic activities are described elsewhere
(9).
The interaction of the synthetic DS 01 with white blood cells was
assessed in the hemograme assay. Fig.
8A shows the comparison of the
total cell count of the blood sample incubated with synthetic DS 01 (128 µg/ml) and the control, in which the blood was submitted to the
same procedures, except for the addition of the peptide. The bar graph
shows that there are no significant differences between populations
found in the control and the experimental group for any of the cell
types analyzed (neutrophils, eosinophils, monocytes, lymphocytes,
basophils, and platelets). Subsequent investigation on leukocyte
morphology was carried out by using light microscopy (Fig.
8B). Once again, when compared with the control
sample (Fig. 8B, panel 1), the cells
subjected to high peptide concentrations (Fig. 8B,
panel 2) showed no detectable morphological alterations.
Atomic Force Microscopy--
DS 01 at a concentration of 30 µg/ml did not cause detectable morphological alterations on the
surface of red blood cells under the experimental conditions used (Fig.
9, B1 and
B2). The erythrocytes maintained their biconcave
discoidal shape and appeared unchanged after the incubation period when
compared with the control sample (Fig. 9, A1 and
A2). Triton X-100-treated erythrocytes, used as
positive control, showed disruption of the cell surface (Fig. 9,
C1 and C2), and many of
them were severely misshapen.
The ever growing number of resistant microorganism strains due to
the abuse of the commercially available antibiotics has stimulated
research on new alternatives for therapy of infections in the area of
novel drugs. Cationic antimicrobial peptides have been considered by
many to be an important component of the so-called primitive immune
system (46). Therefore, these molecules, which play a key role in host
defense against microorganism invasion, seem to be a suitable basis for
further studies. Many drug companies are engaged in systematic
screening for naturally occurring compounds that could be used as a
starting point for new drug design and development. Among these
molecules are the well known dermaseptins, which are present in the
granular glands of the Phyllomedusinae subfamily of frogs
and which display considerable antimicrobial activity against various
kinds of microorganisms. These peptides also have different levels of
activity against Gram-negative and Gram-positive bacteria, fungi
(including yeasts), and protozoa (including the Leishmania
genus) at micromolar concentrations. Importantly, most of the
dermaseptins have little or no hemolytic activity against mammalian
cells at antimicrobial concentrations.
The present study deals with the purification and characterization of a
new antimicrobial peptide named dermaseptin 01 (DS 01) from the skin
secretion of the newly described Brazilian species P. oreades (31). DS 01 possesses all the structural features present
on the dermaseptin polypeptide family (9-12), including amidation at
the C-terminal (Figs. 4 and 5). This peptide is similar in length to DS
V (Table I) isolated from Phyllomedusa sauvagii (12), and
the pairwise sequence alignment of DS 01 and DS V revealed only 59%
amino acid positional identity. A comparison with the adenoregulin
precursor from P. bicolor reveals that the amino acid
positional identity is about 76% (Table I).
When plotted as an Antimicrobial activity of DS 01 was assessed against bacterial strains,
toward which the effectiveness of the dermaseptin family of
antimicrobial peptides was already known, and against the pathogenic
protozoa T. cruzi. The minimal inhibitory concentrations obtained in the antibacterial tests shown in Table II are slightly higher than those reported in the literature (7-11). However, there is
no reason to believe that DS 01 has comparatively lesser antimicrobial
activity than other dermaseptins since there are no standards and the
experimental conditions used in the tests were more severe (on the
order of 107 colony forming units/ml and Mueller-Hinton medium).
The anti-T.cruzi assay reveals that DS 01, DD K, and DD L
are remarkable trypanocidal agents. The protozoan cell population was
reduced to a non-detectable level by these antimicrobial peptides in
concentrations close to 16 µg/ml (~6 µM) after 2 h of incubation. Further incubation only accentuated
dermaseptin-mediated cell lysis, probably due to the greater diffusion
of the peptide through the blood medium. The anti-T.cruzi
activity of the dermaseptins toward the trypomastigote and epimastigote
forms was also investigated in culture and showed very similar results
(data not shown). The effect of antimicrobial peptides on T. cruzi has already been investigated by the use of a cationic
undecapeptide. After the incubation of a 20 µg/ml solution, there was
a decrease of 54.7-10.7% in the infection rate of HeLa cells (47). In
general, protective agents commonly used in blood supplies show little
or no lytic activity against T.cruzi blood forms; their main
effect is limited on the reduction of the mobility of the parasite. On
the other hand, the dermaseptins assayed in this study (DS 01, DD K,
and DD L) induced killing of T.cruzi, most likely by
membrane disruption and cell leakage. Indeed, little or no intact
protozoan cells were found under optical microscopy (data not shown).
The assays performed show that the trypanocidal activity of the
dermaseptins might be a general feature of this family of antimicrobial peptides.
Since the usefulness of DS 01 as a blood treatment agent depends not
only on its trypanocidal activity but also on its lack of toxicity for
the blood cells, some experiments were performed to detect possible
cell alterations upon contact with the peptide. The conventional
hemolysis test, shown in Table III, reveals that DS 01 at
concentrations up to 128 µg/ml has little hemolytic effect. Although
that is clearly an important property for a novel drug candidate, there
is also the need to probe peptide interactions with other cell types.
The effect of DS 01 on leukocytes was assessed through the total cell
count of a blood sample incubated with DS 01 for 4 h. The results,
shown in Fig. 8A, demonstrated that there was no significant
alteration in the frequencies of blood cell populations in either
treated or control samples. Also, when the morphology of the
investigated cells was compared, no detectable differences were found
(Fig. 8B).
AFM was applied as an additional step in the evaluation of
hemolysis and to monitor the morphology of erythrocytes treated with DS
01. The AFM results not only confirmed that DS 01 was not hemolytic for
erythrocytes, as already stated by the conventional analysis, but also
provided an elegant evaluation of the morphological integrity of the
erythrocytes after the exposure to the peptide. Indeed, the AFM result
also suggested that the dermaseptins did not associate to the
erythrocyte membrane in a manner that could damage cell functions or
its overall architecture. This procedure introduces a more refined step
of control on the conventional methods to access cell damaging by drugs
in toxicity bioassays. To the best of our knowledge, this is the first
time that AFM has been used for this purpose.
As stated previously, the dermaseptin family of peptides may have
potential use as therapeutic drugs provided that they are not toxic to
animals or plants. Consistent with the data reported above,
where the antibacterial and trypanocidal activities of DS 01, DD K, and
DD L were demonstrated, combined with their harmless properties to red
and white blood cells, it is clear that these peptides should be
considered important candidates as blood treatment agents.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-cyano-4-hydroxycinnaminic
acid, spotted on a MALDI sample plate, and dried at room temperature. Amino acid sequencing was performed by the automated Edman degradation method on a PPSQ-23 protein peptide sequencer (from Shimadzu Corp.). C-terminal ladder sequencing was also performed on DS 01 using Perseptive Biosystems SequazymeTM C-peptide kit and
MALDI-TOF/MS.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

View larger version (22K):
[in a new window]
Fig. 1.
Crude skin secretion initial
fractionation. The skin secretion of P. oreades was
loaded onto a C18 Vydac 218 TP 510 (10 × 250 mm)
column and equilibrated with 0.1% trifluoroacetic acid. The peptide
elution was performed using an acetonitrile with 0.1% trifluoroacetic
acid solution with 2.5 ml/min flow rate. The absorbance was monitored
simultaneously at two wavelengths (216 and 280 nm).

View larger version (14K):
[in a new window]
Fig. 2.
Further DS 01 purification. A, DS 01 fraction after
analytical RP-HPLC using a C18 Vydac 218 TP 54 (250 × 4.6 mm) column. Peptide fractions were monitored at 216 and 280 nm.
B, MALDI-TOF/MS spectrum showing the molecular mass of DS
01. Sodium and potassium adducts were also detected in the
experiment.

View larger version (15K):
[in a new window]
Fig. 3.
Analysis of the digested fractions.
A, DS 01 fraction after digestion with endoproteinase Glu-C
yielding two fragments (DS 01a and DS 01b). The
separation of the fragments was performed in a Vydac 218 TP 54 (250 × 4.6 mm) column with a three-step gradient (0-30% in 30 min, 30-40% in 20 min, and 40-50% in 10 min) of acetonitrile in
0.1% trifluoroacetic acid/water at a constant flow rate of 1.0 ml/min.
B, MALDI-TOF/MS mass spectrum showing the molecular mass of
the fragment DS 01a ([M+H]+ = 1347.49 Da). C,
mass spectrum of the fragment DS 01b ([M+H]+ = 1437.62 Da).

View larger version (22K):
[in a new window]
Fig. 4.
MALDI-TOF/MS spectra of the carboxypeptidase
Y ladder sequencing of DS 01. Mass intervals (indicated in
parentheses) obtained from the difference of the most
intense isotopic ions of each segment showing the last 7 C-terminal
residues are shown.
![]()
View larger version (7K):
[in a new window]
Fig. 5.
The complete amino acid sequence of DS
01. The long arrow indicates automatic Edman sequencing
of the intact DS 01. Fragmented arrows indicate
endoproteinase Glu-C peptides sequenced by Edman degradation.
Small arrows pointing to the left represent
carboxypeptidase Y (CPY) ladder sequencing using
MALDI-TOF/MS.
Amino acid sequence and similarity analysis
-helical arrangement, obtained upon contact with some organic
solvents or the lipid bilayer (44), also gives the peptides a strong
amphiphilic character, as demonstrated by the helix-wheel plot (Fig.
6).

View larger version (24K):
[in a new window]
Fig. 6.
Helix-Wheel plots. A, peptide
DS 01 showing the amphiphilic character of the molecule. B,
synthetic peptide DD K. C, synthetic peptide DD L. The
residues shown in black, gray, and
white have hydrophobic, charged and polar side chains,
respectively. The first and last residues of each turn have the
corresponding number written at their side.
Antibacterial activity of the dermaseptin DS 01

View larger version (18K):
[in a new window]
Fig. 7.
Anti-T.cruzi bioassays.
Lytic activity of DS 01, DD K, and DD L against T.cruzi
trypomastigote forms grown in blood media at different incubation
times, 2 (A) and 6 h (B).
Hemolytic activity of the dermaseptin DS 01

View larger version (51K):
[in a new window]
Fig. 8.
Hemograme. A, bar graphs
showing white blood cell populations subjected to DS 01 at 128 µg/ml
and corresponding standard deviations. B, morphological
monitoring of neutrophyls (I), lymphocytes (II),
monocytes (III), and eosinophyls (IV) of the
control (panel 1) and experimental cell samples (panel
2).

View larger version (89K):
[in a new window]
Fig. 9.
AFM monitoring of red blood cells.
Three-dimensional view AFM images (43 × 43 µm) of a normal
blood film (A), peptide-treated blood film (B),
and Triton X-100-treated blood film (C) are shown.
Three-dimensional view high-magnification AFM images of isolated normal
erythrocyte (D), isolated peptide-treated erythrocyte
(E), and isolated Triton X-100-treated erythrocyte
(F) are also shown.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-helical wheel, DS 01 showed the distinguishable
polar and apolar domains (Fig. 6). The propensity of small-sized
cationic peptides to form
-helical amphiphilic structures in apolar
medium has been proposed to be a prerequisite for their membranolytic
activity (16-20).
| |
ACKNOWLEDGEMENTS |
|---|
We thank Conselho Nacional de Desenvolvimento Científico e Tecnológico for the scholarship support and Empresa Brasileira de Pesquisa Agropecuária (EMBRAPA) Genetic Resources and Biotechnology for providing the mass spectrometry and sequencing facilities. We are also grateful to Beatriz S. Magalhães, Natacha C. F. Santos, and José R. Furtado, Jr., for technical expertise and to Dr. Isabel Santos for invaluable remarks and manuscript corrections.
| |
FOOTNOTES |
|---|
* The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
¶¶ To whom correspondence should be addressed: Laboratório de Espectrometria de Massa, EMBRAPA - Recursos Genéticos e Biotecnologia, Estação Parque Biológico, Final W5, Asa Norte, Brasília, DF, 70770-900, Brazil. Tel.: 55-61-448-4636; Fax: 55-61-340-3658; E-mail: cbloch@cenargen.embrapa.br.
Published, JBC Papers in Press, October 11, 2002, DOI 10.1074/jbc.M209289200
| |
ABBREVIATIONS |
|---|
The abbreviations used are: DS 01, dermaseptin 01; DD K, dermadistinctin K; DD L, dermadistinctin L; HPLC, high pressure liquid chromatography; RP-HPLC, reverse-phase HPLC; MALDI-TOF/MS, matrix-assisted laser desorption/ionization-time of flight/mass spectrometry; Fmoc, N-(9-fluorenyl)methoxycarbonyl; AFM, atomic force microscopy.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Jung, G. (1991) Angew. Chem. Int. Ed. Engl. 30, 1051-1068 |
| 2. | Kolter, R., and Moreno, F. (1992) Annu. Rev. Microbiol. 46, 141-163[CrossRef][Medline] [Order article via Infotrieve] |
| 3. | Klaenhammer, T. R. (1993) FEMS Microbiol. Rev. 12, 39-86[Medline] [Order article via Infotrieve] |
| 4. |
Jack, R. W.,
Tagg, J. R.,
and Ray, B.
(1995)
Microbiol. Rev.
59,
171-200 |
| 5. | Venema, K., Venema, F., and Kok, J. (1995) Trends Microbiol. 3, 299-304[CrossRef][Medline] [Order article via Infotrieve] |
| 6. | Amiche, M., Seon, A. A., Pierre, T. N., and Nicolas, P. (1999) FEBS Lett. 456, 352-356[CrossRef][Medline] [Order article via Infotrieve] |
| 7. | Ammar, B., Périanin, A., Mor, A., Sarfati, G., Tissot, M., Nicolas, P., Giroud, J. P., and Roch-Arveiller, M. (1998) Biochem. Biophys. Res. Commun. 247, 870-875[CrossRef][Medline] [Order article via Infotrieve] |
| 8. | Nicolas, P., and Mor, A. (1995) Annu. Rev. Microbiol. 49, 277-304[CrossRef][Medline] [Order article via Infotrieve] |
| 9. | Batista, C. V. F., Rosendo da Silva, L., Sebben, A., Scaloni, A., Ferrara, L., Paiva, G. R., Orlamendi-Portugal, T., Possani, L. D., and Bloch, C., Jr. (1999) Peptides (Elmsford) 20, 679-686 |
| 10. | Mor, A., Amiche, M., and Nicolas, P. (1994) Biochemistry 33, 6642-6650[CrossRef][Medline] [Order article via Infotrieve] |
| 11. |
Mor, A.,
Hani, K.,
and Nicolas, P.
(1994)
J. Biol. Chem.
269,
31635-31641 |
| 12. | Mor, A., and Nicolas, P. (1994) Eur. J. Biochem. 219, 145-154[Medline] [Order article via Infotrieve] |
| 13. |
Daly, J. W.,
Caceres, J.,
Moni, R. W.,
Gusovsky, F.,
Moos, M., Jr.,
Seamon, K. B.,
Milton, K.,
and Myers, C. W.
(1992)
Proc. Natl. Acad. Sci. U. S. A.
89,
10960-10963 |
| 14. | Mor, A., Nguyen, V. H., Delfour, A., Migliori-Smour, D., and Nicolas, P. (1991) Biochemistry 30, 8824-8830[CrossRef][Medline] [Order article via Infotrieve] |
| 15. | Shai, Y., and Oren, Z. (2001) Peptides (Elmsford) 22, 1629-1641 |
| 16. | La Rocca, P., Biggin, P. C., Tieleman, D. P., and Sansom, M. S. P. (1999) Biochim. Biophys. Acta. 1462, 185-200[Medline] [Order article via Infotrieve] |
| 17. | White, S. H., and Wimley, W. C. (1998) Biochim. Biophys. Acta 1376, 339-352[Medline] [Order article via Infotrieve] |
| 18. | Ladhokin, A. S., and White, S. H. (2001) Biochem. Biophys. Acta 1514, 253-260[Medline] [Order article via Infotrieve] |
| 19. | Sitaram, N., and Nagaraj, R. (1999) Biochim. Biophys. Acta. 1462, 29-54[Medline] [Order article via Infotrieve] |
| 20. | Dathe, M., Meyer, J., Beyermann, M., Maul, B., Hoischen, C., and Bienert, M. (2002) Biochim. Biophys. Acta. 1558, 171-186[Medline] [Order article via Infotrieve] |
| 21. | Prenner, E. J., Lewis, R. N. A. H., Jelokhani-Niaraki, M., Hodges, R. S., and McElhaney, R. N. (2001) Biochim. Biophys. Acta 1510, 83-92[Medline] [Order article via Infotrieve] |
| 22. | Matsuzaki, K., Sugishita, K., Fujii, N., and Miyajima, K. (1995) Biochemistry 34, 3423-3429[CrossRef][Medline] [Order article via Infotrieve] |
| 23. | Agusti, R., Couto, A. S., Alves, M. J. M., Colli, W., and de Lederkremer, R. M. (2000) Mem. Inst. Oswaldo Cruz 95, 97-102[Medline] [Order article via Infotrieve] |
| 24. | Voorheis, H. P., Gale, J. S., Owen, M. J., and Edwards, W. (1979) Biochem. J. 180, 11-24[Medline] [Order article via Infotrieve] |
| 25. | Rodrigues, C. O., Catisti, R., Uyemura, S. A., Vercesi, A. E., Lira, R., Rodriguez, C., Urbina, J. A., and Docampo, R. (2001) J. Eukaryot. Microbiol. 48, 588-594[CrossRef][Medline] [Order article via Infotrieve] |
| 26. | Coppens, I., and Courtoy, P. J. (1995) Mol. Biochem. Parasitol. 73, 179-188[CrossRef][Medline] [Order article via Infotrieve] |
| 27. | Gillett, M. P., and Owen, J. S. (1991) Trans. R. Soc. Trop. Med. Hyg. 85, 612-616[CrossRef][Medline] [Order article via Infotrieve] |
| 28. | Hernandez, C., Mor, A., Dagger, F., Nicolas, P, Hernandez, A., Benedetti, E. L., and Dunia, I. (1992) Eur. J. Cell Biol. 59, 414-24[Medline] [Order article via Infotrieve] |
| 29. |
Krugliak, M.,
Feder, R.,
Zolotarev, V. Y.,
Gaidukov, L.,
Dagan, A.,
Ginsburg, H.,
and Mor, A.
(2000)
Antimicrob. Agents Chemother.
44,
2442-2451 |
| 30. |
Efron, L.,
Dagan, A.,
Gaidukov, L.,
Ginsburg, H.,
and Mor, A.
(2002)
J. Biol. Chem.
277,
24067-24072 |
| 31. | Brandão, R. A. A. (2002) J. Herpetol., in press |
| 32. | Mocaio, A. (1997) World Health Stat. Q. 50, 195-198[Medline] [Order article via Infotrieve] |
| 33. | Storino, R., Auger, S., and Miguel, J. (1997) Medicina (B. Aires) 57, 512-516 |
| 34. | Sorensen, S. B., Sorensen, T. L., and Bredd, K. (1991) FEBS Lett. 294, 195-197[CrossRef][Medline] [Order article via Infotrieve] |
| 35. |
Houmard, J.,
and Drapeau, J. R.
(1972)
Proc. Natl. Acad. Sci. U. S. A.
69,
3506-3509 |
| 36. | National Committee for Clinical Laboratory Standards. (1999) Performance Standards for Antimicrobial Susceptibility Testing, NCCLS-approved standard M100-S9 , National Committee for Clinical Laboratory Standards, Wayne, PA |
| 37. | Bulet, P., Cociancich, S., Dimarcq, J-L., Lambert, J., Hoffmann, D., and Hoffmann, J. A. (1991) J. Biol. Chem. 236, 24520-24525 |
| 38. | Park, C. B., Kim, M. S., and Kim, S. C. (1996) Biochem. Biophys. Res. Commun. 218, 408-413[CrossRef][Medline] [Order article via Infotrieve] |
| 39. | Silva, J. S., Ferrioli-Filho, F., Kanesiro, M. M., Santos, S. C., Pinto, C. N., Gilbert, B., Ribeiro, F. W., and Pinto, A. V. (1992) Mem. Inst. Oswaldo Cruz 87, 345-351[Medline] [Order article via Infotrieve] |
| 40. | Bignami, G. S. (1993) Toxicon 31, 817-820[Medline] [Order article via Infotrieve] |
| 41. | Ben-Ezra, J., Louis, M. S., and Riley, R. S. (2001) Lab. Hematol. 7, 61-64 |
| 42. | Hove, L. V., Chisano, T. S., and Brace, L. (2000) Lab. Hematol. 6, 93-108 |
| 43. | Aboudy, Y., Mendelson, E., Shalit, I., Bessalle, R., and Fridikin, M. (1994) Int. J. Pept. Protein Res. 43, 573-582[Medline] [Order article via Infotrieve] |
| 44. | Dathe, M., Nikolenko, H., Meyer, J., Beyermann, M., and Bienert, M. (2001) FEBBS Lett. 501, 146-150[CrossRef][Medline] [Order article via Infotrieve] |
| 45. | Pierre, T. N., Seon, A. A., Amiche, M., and Nicolas, P. (2000) Eur. J. Biochem. 267, 370-378[Medline] [Order article via Infotrieve] |
| 46. | Salzet, M. (2001) Trends Immunol. 22 (6), 285-288[CrossRef][Medline] [Order article via Infotrieve] |
| 47. | Nakajima-Shimada, J., Natori, S., and Aoki, T. (1998) Parasitol. Intern. 47, 203-209 |
This article has been cited by other articles:
![]() |
S. Rotem, I. Radzishevsky, and A. Mor Physicochemical properties that enhance discriminative antibacterial activity of short dermaseptin derivatives. Antimicrob. Agents Chemother., August 1, 2006; 50(8): 2666 - 2672. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. S. Radzishevsky, S. Rotem, F. Zaknoon, L. Gaidukov, A. Dagan, and A. Mor Effects of Acyl versus Aminoacyl Conjugation on the Properties of Antimicrobial Peptides Antimicrob. Agents Chemother., June 1, 2005; 49(6): 2412 - 2420. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Balaban, Y. Gov, A. Giacometti, O. Cirioni, R. Ghiselli, F. Mocchegiani, F. Orlando, G. D'Amato, V. Saba, G. Scalise, et al. A Chimeric Peptide Composed of a Dermaseptin Derivative and an RNA III-Inhibiting Peptide Prevents Graft-Associated Infections by Antibiotic-Resistant Staphylococci Antimicrob. Agents Chemother., July 1, 2004; 48(7): 2544 - 2550. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. V. Prates, M. L. Sforca, W. C. B. Regis, J. R. S. A. Leite, L. P. Silva, T. A. Pertinhez, A. L. T. Araujo, R. B. Azevedo, A. Spisni, and C. Bloch Jr. The NMR-derived Solution Structure of a New Cationic Antimicrobial Peptide from the Skin Secretion of the Anuran Hyla punctata J. Biol. Chem., March 26, 2004; 279(13): 13018 - 13026. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Noinville, F. Bruston, C. El Amri, D. Baron, and P. Nicolas Conformation, Orientation, and Adsorption Kinetics of Dermaseptin B2 onto Synthetic Supports at Aqueous/Solid Interface Biophys. J., August 1, 2003; 85(2): 1196 - 1206. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||